Business Wire

FDA Approves ZONTIVITY™ (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with ...

First-in-Class PAR-1 Antagonist ZONTIVITY is the first and only therapy shown to inhibit the protease-activated receptor-1 (PAR-1), the primary receptor for thrombin, which is considered to be the ...
Reuters

Schering-Plough's oral thrombin receptor antagonist meets primary endpoint in Phase II trial

Co announces the results of a Phase II trial of its oral thrombin receptor antagonist SCH 530348 in a clinical trial session at the annual Scientific Sessions of the American College of Cardiology/i2 ...
Medscape

Novel antiplatelet "may reduce events without increasing bleeding"

New Orleans, LA - A novel oral antiplatelet agent has shown promising results in a phase 2 trial in patients undergoing elective stenting, showing a trend toward fewer ischemic events without ...
Medscape

Vorapaxar Stumbles in ACS, Ups Bleeding Risk: TRACER

November 13, 2011 (Orlando, Florida) — A novel oral antithrombotic agent, given to high-risk patients with non-ST-elevation ACS who were mostly already on dual-agent antiplatelet therapy, failed to ...
Reuters

Schering-Plough reports two Phase II studies of thrombin receptor antagonist build on findings from previous Phase II study

Co provides an update on the clinical development program for its oral thrombin receptor antagonist. Results from two randomized, double-blind, placebo-controlled Phase II studies in patients with ...